Johnson & Johnson CEO celebrates company’s cardiovascular business during Q4 earnings call
Johnson & Johnson reported $24.6 billion in sales for the fourth quarter of 2025, up 9.1% from the previous year. That was good for a net earnings of $5.1 billion at $2.10 per share.
In addition, the company added, overall sales were $94.2 billion for all of 2025, up 6% from the previous year, with a net earnings of $26.8 billion at $11.03 per share.
When looking at non-GAAP figures that excluded one-time transactions, meanwhile, the company reported an adjusted earnings of $2.46 per share for the fourth quarter and $10.79 per share for the full year.
Johnson & Johnson MedTech making an impact
Reviewing these data, Johnson & Johnson highlighted the growing importance of its Johnson & Johnson MedTech brand, which includes Shockwave Medical as well as the technologies gained from its acquisitions of Abiomed, Biosense Webster and other medtech companies in the cardiovascular health space.
Johnson & Johnson MedTech was linked to sales of $8.8 billion, up 7.5% from the previous year, for the fourth quarter of 2025 and $33.8 billion, up 6.1%, for the full year.
“2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history” Joaquin Duato, chairman and CEO of Johnson & Johnson, said in a statement. “Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: oncology, immunology, neuroscience, cardiovascular, surgery and vision. In each of these important areas, our leadership is expanding, driven by game-changing science and technology.”
During an earnings call, Duato celebrated the “strong” performance of Johnson & Johnson MedTech’s cardiovascular business and the “accelerated momentum” in its surgery and vision businesses. In total, Johnson & Johnson Medtech achieved more than 40 regulatory approvals and 15 product launches in major markets. In addition, more than 60 clinical trials are currently evaluating the safety and/or effectiveness of Johnson & Johnson MedTech products.
Duato also specifically called out how excited the company was about Shockwave Medical’s intravascular lithotripsy (IVL) technology and celebrated the early success of the Varipulse Pulsed Field Ablation (PFA) Platform.
“We remain the market leader in electrophysiology and we plan to expand our position in PFA,” Duato said.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.